News
FOLD
11.78
-0.67%
-0.08
Weekly Report: what happened at FOLD last week (0318-0322)?
Weekly Report · 4d ago
Amicus Therapeutics Price Target Cut to $19.00/Share From $21.00 by JP Morgan
Dow Jones · 03/18 11:59
Amicus Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 03/18 11:59
JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $19
Benzinga · 03/18 11:49
Weekly Report: what happened at FOLD last week (0311-0315)?
Weekly Report · 03/18 10:07
Amicus Therapeut: [Amend]Statement of changes in beneficial ownership of securities
Press release · 03/16 02:06
Weekly Report: what happened at FOLD last week (0304-0308)?
Weekly Report · 03/11 10:05
Amicus Therapeut: Statement of changes in beneficial ownership of securities
Press release · 03/07 00:13
Amicus’s Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones
TipRanks · 03/06 11:19
Weekly Report: what happened at FOLD last week (0226-0301)?
Weekly Report · 03/04 10:07
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)
TipRanks · 03/01 10:21
Buy Rating Affirmed: Amicus’s Strong Product Launch and Growth Trajectory
TipRanks · 03/01 06:04
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
Barchart · 03/01 06:00
Amicus Therapeutics Price Target Maintained With a $22.00/Share by Cantor Fitzgerald
Dow Jones · 02/29 18:57
Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $22 Price Target
Benzinga · 02/29 18:47
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
NASDAQ · 02/29 16:23
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Seeking Alpha · 02/29 15:05
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), TG Therapeutics (TGTX) and Amicus (FOLD)
TipRanks · 02/29 10:40
Needham Sticks to Its Hold Rating for Amicus (FOLD)
TipRanks · 02/29 10:29
Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook
TipRanks · 02/28 20:15
More
Webull provides a variety of real-time FOLD stock news. You can receive the latest news about Amicus Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.